Culturally Targeted & Individually Tailored Smoking Cessation Study: LGBT Smokers

Overview

For the approximately 4.6 million LGBT persons in the U.S., smoking rates among those living in urban areas are roughly twice that of heterosexuals. Targeted interventions have shown great promise in reducing health risk behaviors across a variety of behaviors and population groups by enhancing the relevance of the health information. The primary aim of this study is to test the efficacy of a culturally targeted group-based smoking cessation intervention (vs. a non-targeted intervention) on smoking outcomes among lesbian, gay, bisexual, and transgender (LGBT) smokers. The investigators anticipate that the culturally targeted intervention will be more effective at helping LGBT smokers to successfully stop smoking than will the non-targeted intervention.

Full Title of Study: “A Culturally Targeted and Individually Tailored Smoking Cessation Intervention for LGBT Smokers”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2016

Detailed Description

In Phase 1 of this study we used focus groups to establish the cultural appropriateness and acceptability of the targeted elements of the intervention for the LGBT population. For Phase 2 of this study, we seek to enroll 400 participants in a randomized controlled trial of the targeted intervention vs. a non-targeted, comparison condition. Both conditions will consist of group counseling sessions combined with nicotine replacement therapy and peer support. We expect that quit rates, stage of readiness, perceived benefits, self-efficacy, and treatment adherence will be higher among those who received the targeted intervention than those in the non-targeted intervention. Furthermore, we expect that a stronger LGBT cultural identification and salience of that identity will be associated with more satisfaction and adherence to the targeted intervention.

Interventions

  • Behavioral: Culturally Targeted Cessation Program
    • The culturally targeted version of the behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
  • Behavioral: Non-Targeted Cessation Program
    • Behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.

Arms, Groups and Cohorts

  • Experimental: Culturally Targeted Cessation Program
    • The culturally targeted program will include the same cognitive and behavioral approaches and smoking education content that is used in the standard program. As such, we will maintain the integrity of the core program. However, cultural targeting of that program has been informed by local LGBT focus group input and testing, the available literature on LGBT smoking rates and behaviors, feedback from a panel of LGBT health experts, and data collected as part of a previous study.
  • Active Comparator: Non-Targeted Cessation Program
    • Non-culturally targeted program with cognitive and behavioral approaches and smoking education content.

Clinical Trial Outcome Measures

Primary Measures

  • 7-Day Point Prevalence Smoking Quit Rates 1 Month Post Quit Date
    • Time Frame: Assessed 1 month after quit date
    • 7-Day point prevalence smoking quit rates will serve as the main outcome measure and will be obtained from Time Line Follow-Back (TLFB) interviews.
  • 7-Day Point Prevalence Smoking Quit Rates 3 Months Post Quit Date
    • Time Frame: Assessed 3 months after quit date
    • 7-Day point prevalence smoking quit rates will serve as the main outcome measure and will be obtained from Time Line Follow-Back (TLFB) interviews.
  • 7-Day Point Prevalence Smoking Quit Rates 6 Months Post Quit Date
    • Time Frame: Assessed 6 months after quit date
    • 7-Day point prevalence smoking quit rates will serve as the main outcome measure and will be obtained from Time Line Follow-Back (TLFB) interviews.
  • 7-Day Point Prevalence Smoking Quit Rates 12 Months Post Quit Date
    • Time Frame: Assessed 12 months after quit date
    • 7-Day point prevalence smoking quit rates will serve as the main outcome measure and will be obtained from Time Line Follow-Back (TLFB) interviews.

Participating in This Clinical Trial

Inclusion Criteria

  • Self identify as lesbian, gay, bisexual, or transgender – Age 18-65 – Current cigarette smoker – Desire to quit smoking (self-report rating of interest in quitting) – Relatively healthy, with no medical conditions that would adversely interact with study parameters (see exclusion criteria for specific details) – Agree to attend behavioral counseling sessions, be randomized, and be followed-up – Agrees to use nicotine patch and has no prior adverse reactions to patch – Has stable residence and telephone and can provide the name of an outside household collateral family member or close friend for contact and follow-up.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Illinois at Chicago
  • Collaborator
    • National Institute on Drug Abuse (NIDA)
  • Provider of Information About this Clinical Study
    • Principal Investigator: Alicia Matthews, Associate Professor – University of Illinois at Chicago
  • Overall Official(s)
    • Alicia K Matthews, Ph.D., Principal Investigator, University of Illinois at Chicago

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.